Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

MannKind Narrows First Quarter Loss, Awaits FDA Approval

By Pharmaceutical Processing | May 10, 2011

 

VALENCIA,
Calif. (AP) — MannKind Corp.,
which is seeking government approval for an inhaled insulin treatment, narrowed
its first-quarter loss as it cut its research and development costs.

The loss of $41.5 million, or 34 cents per share, compares
to a loss of $44.7 million, or 40 cents per share, in the same quarter a year
ago. Mannkind’s reported revenue of $50,000, compared with zero a year earlier.

Analysts were expecting a loss of 29 cents per share,
excluding one-time items, and no revenue, according to FactSet.

Valencia-based MannKind said it spent $26.3 million on
research and development in the quarter, a 14 percent decrease from the prior
year primarily due to the termination of an insulin supply agreement. The
company did not put a number on its adjusted earnings.

General expenses increased 16 percent to $11.8 million in
the quarter, largely due to severance payments. The company laid off 179
workers, or 40 percent of its staff, in February to conserve cash.

MannKind said Monday that it had $47.5 million at the end of
March, down from $70.4 million at the end of December.

The U.S. Food and Drug Administration told the company to
run additional trials on its drug, Afrezza, in January. MannKind Chairman and
CEO Alfred Mann said Monday that the company recently held productive meetings
with the FDA and expects to initiate clinical studies in the U.S., Europe and Latin
America once it meets the FDA’s requirements.

MannKind shares fell 60 cents, or 13 percent, to $3.80 in
after-market trading after the company reported its financial results. They had
ended regular trading up 5 cents at $4.40.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE